| Trial ID: | L4661 |
| Source ID: | NCT04733508
|
| Associated Drug: |
111in-Dtpa-Exendin-4
|
| Title: |
Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes
|
| Acronym: |
GLP1R-T2D
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: 111In-DTPA-exendin-4|DRUG: IRDye800CW-exendin-4
|
| Outcome Measures: |
Primary: Pancreatic exendin uptake 111In-DTPA exendin-4, The pancreatic uptake of 111In-DTPA-exendin-4 will be quantified using ex vivo SPECT, 111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using ex vivo SPECTof the resected tissue one day after surgery|Pancreatic exendin uptake 111In-DTPA exendin-4, The pancreatic uptake of 111In-DTPA-exendin-4 will be quantified using tissue autoradiography, 111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined with tissue autoradiography immediately after resection|Beta cell function, The beta cell function will be determined with a glucose tolerance test, The glucose tolerance test will be performed within a week before planned surgery|Blood glucose levels, Glycemic control will be determined by monitoring blood glucose levels, Blood glucose levels will be continuously monitored a week prior to surgery|HbA1C levels, HbA1C levels will be determined as a measure of glycemic control, HbA1C levels will be determined within a week before planned surgery|Pancreatic exendin uptake IRDye800CW-exendin-4, Uptake of IRDye800CW-exendin4 will be visualized with microscopy, IRDye800CW-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using microscopy in the excised tissue|Gene expression, Gene expression levels will be determined with quantitative polymerase chain reaction (qPCR), Gene expression will be determined in the excised pancreatic tissue immediately after resection |
|
| Sponsor/Collaborators: |
Sponsor: Radboud University Medical Center | Collaborators: University of Coimbra
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2019-11-01
|
| Completion Date: |
2022-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2021-02-02
|
| Locations: |
Radboud University Medical Center, Nijmegen, Gelderland, 6525 GA, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT04733508
|
